The frequency of Muir-Torre syndrome among Lynch syndrome families

Journal of the National Cancer Institute

Volumn 100, Issue 4, 2008, Pages 277-281

  South, Christopher D ^a   Hampel, Heather ^b   Comeras, Ilene ^b   Westman, Judith A ^b   Frankel, Wendy L ^a   De La Chapelle, Albert ^b,c  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c Tzagournis Medical Research Facility   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MISMATCH REPAIR PROTEIN PMS2; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; MSH2 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ARTICLE; CANCER GENETICS; CANCER PATIENT; CANCER SCREENING; CANCER SUSCEPTIBILITY; COHORT ANALYSIS; COLON CANCER; COLORECTAL CANCER; COLORECTAL CARCINOMA; COMPARATIVE STUDY; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; FAMILIAL CANCER; FAMILY COUNSELING; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; INCIDENCE; KERATOACANTHOMA; MAJOR CLINICAL STUDY; MALE; MUIR TORRE SYNDROME; POPULATION GENETIC PARAMETERS; PRIORITY JOURNAL; SEBACEOUS CARCINOMA; SKIN TUMOR; SMALL INTESTINE CANCER; TRANSITIONAL CELL CARCINOMA; URETER CANCER; UTERUS CANCER; COLORECTAL TUMOR; GENETIC PREDISPOSITION; GENETICS; MISMATCH REPAIR; MUTATION;

COHORT STUDIES; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA MISMATCH REPAIR; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; INCIDENCE; MUTS HOMOLOG 2 PROTEIN; SKIN NEOPLASMS;

EID: 39649093644     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djm291     Document Type: Article

References (21)

1. Aaltonen LA, Peltomaki P, Leach FS, et al. Clues to the pathogenesis of familial colorectal cancer. Science. 1993;260(5109):812-816.
2. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348 (10):919-932.
3. Watson P, Riley B. The tumor spectrum in the Lynch syndrome. Fam Cancer. 2005;4(3):245-248.
4. Lynch HT, Lynch PM, Pester J, Fusaro RM. The cancer family syndrome. Rare cutaneous phenotypic linkage of Torre's syndrome. Arch Intern Med. 1981;141(5):607-611.
5. Thibodeau SN, French AJ, Roche PC, et al. Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res. 1996;56:4836-4840.
6. Entius MM, Keller JJ, Drillenburg P, Kuypers KC, Giardiello FM, Offerhaus GJ. Microsatellite instability and expression of hMLH-1 and hMSH-2 in sebaceous gland carcinomas as markers for Muir-Torre syndrome. Clin Cancer Res. 2000;6:1784-1789.
7. Kruse R, Rutten A, Schweiger N, et al. Frequency of microsatellite instability in unselected sebaceous gland neoplasias and hyperplasias. J Invest Dermatol. 2003;120(5):858-864.
8. Popnikolov NK, Gatalica Z, Colome-Grimmer MI, Sanchez RL. Loss of mismatch repair proteins in sebaceous gland tumors. J Cutan Pathol. 2003;30(3):178-184.
9. Mathiak M, Rutten A, Mangold E, et al. Loss of DNA mismatch repair proteins in skin tumors from patients with Muir-Torre syndrome and MSH2 or MLH1 germline mutations: establishment of immunohistochemical analysis as a screening test. Am J Surg Pathol. 2002;26(3):338-343.
10. Bapat B, Xia L, Madlensky L, et al. The genetic basis of Muir-Torre syndrome includes the hMLH1 locus. Am J Hum Genet. 1996;59(3):736-739.
11. Ponti G, Ponz de Leon M, Losi L, et al. Different phenotypes in Muir-Torre syndrome: clinical and biomolecular characterization in two Italian families. Br J Dermatol. 2005;152(6):1335-1338.
12. Mangold E, Pagenstecher C, Leister M, et al. A genotype-phenotype correlation in HNPCC: strong predominance of msh2 mutations in 41 patients with Muir-Torre syndrome. J Med Genet. 2004;41:567-572.
13. Machin P, Catasus L, Pons C, et al. Microsatellite instability and immunostaining for MSH-2 and MLH-1 in cutaneous and internal tumors from patients with the Muir-Torre syndrome. J Cutan Pathol. 2002;29(7):415-420.
14. Akhtar S, Oza KK, Khan SA, Wright J. Muir-Torre syndrome: case report of a patient with concurrent jejunal and ureteral cancer and a review of the literature. J Am Acad Dermatol. 1999;41(5 Pt 1):681-686.
15. Ponti G, Losi L, Di Gregorio C, et al. Identification of Muir-Torre syndrome among patients with sebaceous tumors and keratoacanthomas: role of clinical features, microsatellite instability, and immunohistochemistry. Cancer. 2005;103(5):1018-1025.
16. Ponti G, Losi L, Pedroni M, et al. Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas. J Invest Dermatol. 2006;126:2302-2307.
17. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for Cancer Detection and Familial Predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58 :5248-5257.
18. Nakagawa H, Lockman JC, Frankel WL, et al. Mismatch repair gene PMS2: disease-causing germline mutations are frequent in patients whose tumors stain negative for PMS2 protein, but paralogous genes obscure mutation detection and interpretation. Cancer Res. 2004;64:4721-4727.
19. Lynch HT, Leibowitz R, Smyrk T, et al. Colorectal cancer and the Muir-Torre syndrome in a Gypsy family: a review. Am J Gastroenterol. 1999;94(3):575-580.
20. Arnold A, Payne S, Fisher S, et al. An individual with Muir-Torre syndrome found to have a pathogenic MSH6 gene mutation. Fam Cancer. 2007;6(3):317-321.
21. Desai DC, Lockman JC, Chadwick RB, et al. Recurrent germline mutation in MSH2 arises frequently de novo. J Med Genet. 2000;37:646-652.